DDRE-09. DEVELOPING IDO-PROTACS TO IMPROVE IMMUNOTHERAPEUTIC EFFICACY IN PATIENTS WITH GLIOBLASTOMA

INTRODUCTION: Indoleamine 2,3-dioxygenase 1 (IDO; IDO1) is a rate-limiting enzyme that metabolizes the essential amino acid tryptophan into kynurenine. Recent work by our group has revealed that IDO promotes tumor development and suppresses immune cell functions independent of its enzyme activity. M...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Bollu, Lakshmi, Wainwright, Derek, Zhai, Lijie, Ladomersky, Erik, Lauing, Kristen, Bell, April, Schlitz, Gary
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Drug Discovery, Drug Resistance
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651014/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.254
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak